Ponatinib is clinically approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, specifically targeting the BCR-ABL gene mutation, T315I (Tan et al., 2019). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.